EUVIMEDEUVIMED entdecken
Open Access

Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer

Giselle Alexandra Suero-Abreu iD, Zsofia D Drobni, Carlos A Gongora iD, Jana Taron iD, Julia Karady iD, Hannah K Gilman, Bela Merkely iD, Hajnalka Vago, Zoltan V Varga iD, Ryan J Sullivan iD, Kerry L Reynolds iD, Daniel Zlotoff iD und 3 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.125.041925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Giselle Alexandra Suero-Abreu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Program, Division of Cardiology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Plaque, Atherosclerotic, Neoplasms, Atherosclerosis. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are associated with a 3‐fold risk of atherosclerotic cardiovascular disease (ASCVD). However, the biology of atherosclerosis is different among women and men, and ASCVD risk factors among women treated with an ICI are incompletely understood. This study aimed to identify factors associated with ASCVD in women following ICIs and to characterize plaque progression.

Methods

In a single‐center retrospective study, clinical and cancer‐related factors were compared among women treated with ICIs who did and did not experience ASCVD. Competing risk analysis estimated the effect of ICIs on cardiovascular risk. In an imaging substudy, the rate of atherosclerotic plaque progression post‐treatment was compared between women and men.

Results

Among 1188 female patients treated with an ICI, 54 (5%) experienced an ASCVD with a median time to event of 174 days. Patients with ASCVD had a higher prevalence of prior myocardial infarction and coronary revascularization (15% versus 6%, P =0.007) and prior stroke (7% versus 2%, P =0.039). Competing risk analyses, adjusting for cardiovascular risk factors, revealed an almost 3‐fold increased risk of post‐ICI ASCVD in women with prior cardiovascular events (hazard ratio, 2.71 [95% CI, 1.24–5.95]; P =0.013). In an imaging study, the annual rate of plaque progression post‐ICI was 6% for total and 7% for non‐calcified plaque, with similar rates of progression observed in women and men.

Conclusions

In female patients treated with ICIs, 5% developed an ASCVD, and a history of cardiovascular events was a risk factor. In an imaging study, plaque progressed in a short time frame after ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPlaque, AtheroscleroticNeoplasmsAtherosclerosisHumansFemaleRetrospective StudiesDisease ProgressionAgedMiddle AgedMaleRisk AssessmentSex FactorsRisk FactorsTime Factors

Stichwörter der Autor:innen

atherosclerotic cardiovascular diseasecardiotoxicityimmune checkpoint inhibitorsplaque progressionsex‐specific

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Cardio-Oncology Program, Division of Cardiology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.
  • Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology Massachusetts General Hospital, Harvard Medical School Boston MA USA.
  • Heart and Vascular Center Semmelweis University Budapest Hungary.
  • Department of Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg Freiburg Germany.
  • MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Center for Pharmacology and Drug Research & Development, Department of Pharmacology and Pharmacotherapy Semmelweis University Budapest Hungary.
  • Division of Oncology and Hematology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA USA.

ORCID-Profile: Giselle Alexandra Suero-Abreu, Carlos A Gongora, Jana Taron, Julia Karady, Bela Merkely, Zoltan V Varga, Ryan J Sullivan, Kerry L Reynolds, Daniel Zlotoff, Borek Foldyna, Markella V Zanni, Tomas G Neilan

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Suero-Abreu, G. A., Drobni, Z. D., Gongora, C. A., Taron, J., Karady, J., Gilman, H. K., Merkely, B., Vago, H., Varga, Z. V., Sullivan, R. J., Reynolds, K. L., Zlotoff, D., Foldyna, B., Zanni, M. V., & Neilan, T. G. (2025). Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041925

Vancouver

Suero-Abreu GA, Drobni ZD, Gongora CA, Taron J, Karady J, Gilman HK, et al. Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041925

BibTeX
@article{SueroAbreu2025,
  author = {Suero-Abreu, Giselle Alexandra and Drobni, Zsofia D and Gongora, Carlos A and Taron, Jana and Karady, Julia and Gilman, Hannah K and Merkely, Bela and Vago, Hajnalka and Varga, Zoltan V and Sullivan, Ryan J and Reynolds, Kerry L and Zlotoff, Daniel and Foldyna, Borek and Zanni, Markella V and Neilan, Tomas G},
  title = {Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.125.041925}
}
Kostenlos starten →